Nucleolin and nucleophosmin expression patterns in pulmonary adenocarcinoma invading the pleura and in pleural malignant mesothelioma.


Journal

Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441

Informations de publication

Date de publication:
09 2020
Historique:
received: 13 05 2020
revised: 16 06 2020
accepted: 17 06 2020
pubmed: 17 7 2020
medline: 16 11 2021
entrez: 17 7 2020
Statut: ppublish

Résumé

Visceral pleural invasion (VPI) in adenocarcinoma of the lung is considered a poor prognostic factor. The purpose of this study was to analyze nucleolin and nucleophosmin expression in pulmonary adenocarcinoma (PA) with VPI and in pleural malignant mesothelioma. The study was conducted on the basis of 19 pathologically-confirmed cases of adenocarcinoma of the lung and 29 cases of epithelioid malignant mesothelioma. The nucleolin and nucleophosmin expression was assessed immunohistochemically and analyzed with image analysis software. Nucleolin expression was lower while nucleophosmin was higher in pleural invasion of pulmonary adenocarcinoma than in the central part of the tumor. Differences in subpopulations of cells with different expression of proteins studied were also found. Malignant mesothelioma showed lower nucleolin expression than adenocarcinoma of the lung but no differences in nucleophosmin expression were found. The results of our study suggested that lower nucleolin and higher nucleophosmin expression may be related to higher invasiveness of adenocarcinoma of the lung. Differences in nucleolin expression between pulmonary adenocarcinoma and malignant mesothelioma indicate another aspect of biology of these pleura-invading cancers that requires further study. SIGNIFICANT FINDINGS OF THE STUDY: Differences in nucleolin and nucleophosmin expression in pleura invading pulmonary adenocarcinoma indicate the involvement of these proteins in its locoregional spread while differences in nucleolin expression between pulmonary adenocarcinoma and malignant mesothelioma suggest another aspect of biology of these cancers. This is the first study on nucleolin and nucleophosmin expression in pleural malignant mesothelioma and pleura-invading pulmonary adenocarcinoma. Our findings may assist in understanding the mechanisms of locoregional spread of adenocarcinoma and differences between these two pleura-invading cancers.

Sections du résumé

BACKGROUND
Visceral pleural invasion (VPI) in adenocarcinoma of the lung is considered a poor prognostic factor. The purpose of this study was to analyze nucleolin and nucleophosmin expression in pulmonary adenocarcinoma (PA) with VPI and in pleural malignant mesothelioma.
METHODS
The study was conducted on the basis of 19 pathologically-confirmed cases of adenocarcinoma of the lung and 29 cases of epithelioid malignant mesothelioma. The nucleolin and nucleophosmin expression was assessed immunohistochemically and analyzed with image analysis software.
RESULTS
Nucleolin expression was lower while nucleophosmin was higher in pleural invasion of pulmonary adenocarcinoma than in the central part of the tumor. Differences in subpopulations of cells with different expression of proteins studied were also found. Malignant mesothelioma showed lower nucleolin expression than adenocarcinoma of the lung but no differences in nucleophosmin expression were found.
CONCLUSIONS
The results of our study suggested that lower nucleolin and higher nucleophosmin expression may be related to higher invasiveness of adenocarcinoma of the lung. Differences in nucleolin expression between pulmonary adenocarcinoma and malignant mesothelioma indicate another aspect of biology of these pleura-invading cancers that requires further study.
KEY POINTS
SIGNIFICANT FINDINGS OF THE STUDY: Differences in nucleolin and nucleophosmin expression in pleura invading pulmonary adenocarcinoma indicate the involvement of these proteins in its locoregional spread while differences in nucleolin expression between pulmonary adenocarcinoma and malignant mesothelioma suggest another aspect of biology of these cancers.
WHAT THIS STUDY ADDS
This is the first study on nucleolin and nucleophosmin expression in pleural malignant mesothelioma and pleura-invading pulmonary adenocarcinoma. Our findings may assist in understanding the mechanisms of locoregional spread of adenocarcinoma and differences between these two pleura-invading cancers.

Identifiants

pubmed: 32671956
doi: 10.1111/1759-7714.13564
pmc: PMC7471022
doi:

Substances chimiques

NPM1 protein, human 0
Nuclear Proteins 0
Phosphoproteins 0
RNA-Binding Proteins 0
Nucleophosmin 117896-08-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2529-2535

Informations de copyright

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Références

Biochem Biophys Res Commun. 2010 Jul 2;397(3):499-504
pubmed: 20515654
J Cell Sci. 2007 Jun 15;120(Pt 12):2091-105
pubmed: 17535846
Anticancer Res. 2020 Apr;40(4):1973-1979
pubmed: 32234886
Am J Surg Pathol. 2007 Jun;31(6):953-6
pubmed: 17527086
Biochem Cell Biol. 2016 Oct;94(5):419-432
pubmed: 27673355
APMIS. 2013 Oct;121(10):919-25
pubmed: 23763304
RNA Biol. 2012 Jun;9(6):799-808
pubmed: 22617883
Am J Surg Pathol. 2013 Jul;37(7):1100-8
pubmed: 23681071
Commun Integr Biol. 2011 May;4(3):267-75
pubmed: 21980556
Hum Pathol. 2010 Aug;41(8):1079-86
pubmed: 20338617
Int J Biochem Cell Biol. 2018 Oct;103:65-73
pubmed: 30130654
Tumour Biol. 2016 Aug;37(8):10349-56
pubmed: 26846099
FEBS Lett. 2014 May 21;588(10):1921-9
pubmed: 24713430
Anticancer Res. 2004 Mar-Apr;24(2B):963-6
pubmed: 15161050
J Biomed Sci. 2012 May 25;19:53
pubmed: 22631075
Ann Thorac Surg. 2015 Apr;99(4):1130-9
pubmed: 25704861
APMIS. 2012 Mar;120(3):187-94
pubmed: 22339675
J Thorac Oncol. 2008 Dec;3(12):1384-90
pubmed: 19057261
Arch Pathol Lab Med. 2006 Nov;130(11):1654-61
pubmed: 17076527
Virchows Arch. 2017 Jun;470(6):639-646
pubmed: 28349237
Br J Cancer. 2007 Feb 12;96(3):477-84
pubmed: 17245342
Folia Histochem Cytobiol. 2019;57(3):139-145
pubmed: 31513277
Int J Oncol. 2014 Jul;45(1):264-72
pubmed: 24787960
Virchows Arch. 2014 Dec;465(6):679-85
pubmed: 25300229
Exp Cell Res. 2011 Apr 15;317(7):966-75
pubmed: 21182834
Clin Cancer Res. 2010 Jul 15;16(14):3734-42
pubmed: 20628027
Lung Cancer. 2019 Feb;128:13-19
pubmed: 30642445
Cancer Detect Prev. 2006;30(6):481-90
pubmed: 17113241
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Oncotarget. 2017 Mar 22;8(39):66576-66583
pubmed: 29029538
Urology. 2004 Oct;64(4):839-44
pubmed: 15491744
Clin Exp Metastasis. 2011 Feb;28(2):101-11
pubmed: 21104427
Acta Pharmacol Sin. 2008 Mar;29(3):364-70
pubmed: 18298902

Auteurs

Marek Masiuk (M)

Department of Pathology, Pomeranian Medical University, Szczecin, Poland.

Piotr Waloszczyk (P)

Independent Laboratory of Pathology "Zdunomed" LLC, Szczecin, Poland.

Magdalena Lewandowska (M)

Department of Pathology, Pomeranian Medical University, Szczecin, Poland.

Ewa Dobak (E)

Department of Pathology, Pomeranian Medical University, Szczecin, Poland.

Elzbieta Urasinska (E)

Department of Pathology, Pomeranian Medical University, Szczecin, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH